Humanigen's mAb improves outcomes in hospitalized COVID-19 patients

By The Science Advisory Board staff writers

March 29, 2021 -- Humanigen is highlighting results from a phase III trial that show that its monoclonal antibody (mAb), lenzilumab, improves outcomes in hospitalized COVID-19 patients by keeping them off mechanical ventilators.

The study found that patients who received the drug in combination with other treatments including steroids and remdesivir had a 54% greater relative likelihood of survival without the need for mechanical ventilation compared with patients receiving placebo and other treatments.

Humanigen plans to submit an emergency use authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for lenzilumab.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.